儿童泛发性脓疱型银屑病发病机制及治疗进展

doi:10.12372/jcp.2025.24e1264

Abstract

Abstract:

Generalized pustular psoriasis (GPP) is a rare, recurrent systemic inflammatory skin disease. Interleukin (IL)-36RN (IL36RN) is the most common causative gene in GPP. Innate immunity mediated by IL-1/IL-36-chemokine-neutrophils plays a central role in the pathogenesis of GPP, and adaptive immunity mediated by tumor necrosis factor-α (TNF-α)/IL-23/IL-17 is also involved in GPP pathogenesis. At present, the main therapeutic agents for GPP are acitretin, methotrexate, cyclosporine and biologics. Most of the biologics are still used as over-indications in pediatric GPP. There is increasing evidence that adalimumab and secukinumab have achieved better efficacy in the treatment of GPP in children. Spesolimab, an IL-36 receptor inhibitor, is a new therapeutic target for GPP, bringing new hope for the treatment and prevention of GPP. This article reviews the pathogenesis and treatment progress of GPP in children, and provides reference for the clinical diagnosis and treatment of the disease.

Key words: generalized pustular psoriasis, pathogenesis, treatment progress, biologics, child

CLC Number:

LYU Mingjun, LUO Wen, YANG Jinxiang, LIANG Jianying, YAO Zhirong. Progress in pathogenesis and treatment of pediatric generalized pustular psoriasis[J].Journal of Clinical Pediatrics, 2025, 43(7): 556-562.

References 39

[1]	Choon SE, van de Kerkhof P, Gudjonsson JE, et al. International consensus definition and diagnostic criteria for generalized pustular psoriasis from the international psoriasis council[J]. JAMA Dermatol, 2024, 160(7): 758-768. doi: 10.1001/jamadermatol.2024.0915 pmid: 38691347
[2]	Feng JN, Guo JZ, Zhang Q, et al. Higher prevalence of generalized pustular psoriasis in Asia? A population-based study using claim data in China and a systematic review[J]. Dermatology, 2023, 239(2): 195-205.
[3]	Choon SE, De La Cruz C, Wolf P, et al. Health-related quality of life in patients with generalized pustular psoriasis: a systematic literature review[J]. J Eur Acad Dermatol Venereol, 2024, 38(2): 265-280.
[4]	Zhao A, Li M. Understanding the pathogenesis of generalized pustular psoriasis based on molecular genetics and immunopathology[J]. Int J Dermatol Venereol, 2022, 5(4): 199-206.
[5]	Krueger JG, Pagotto A, Haftel S, et al. Targeted review of IL36RN mutations in patients with generalised pustular psoriasis[J]. Skin Health Dis, 2024, 4(2): e343.
[6]	Yoshikawa T, Takeichi T, Nishida K, et al. MEFV variants are a predisposing factor for generalized pustular psoriasis[J]. J Am Acad Dermatol, 2024, 90(4): 852-854.
[7]	Chen J, Xue X, Wang Z, et al. Genetic analysis of different subtypes of aseptic pustulosis in the Chinese population[J]. Clin Exp Dermatol, 2024, 49(10): 1217-1226.
[8]	Choon SE, Foley PA, Asawanonda P, et al. Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis[J]. J Dermatol, 2024, 51(12): 1579-1595.
[9]	Wang Z, Xiang X, Chen Y, et al. Different clinical features of pediatric generalized pustular psoriasis in patients with or without IL36RN variants[J]. Dermatology, 2023, 239(2): 217-226.
[10]	Uppala R, Tsoi LC, Harms PW, et al. "Autoinflammatory psoriasis"-genetics and biology of pustular psoriasis[J]. Cell Mol Immunol, 2021, 18(2): 307-317.
[11]	Sugiura K, Fujita H, Komine M, et al. The role of interleukin-36 in health and disease states[J]. J Eur Acad Dermatol Venereol, 2024, 38(10): 1910-1925. doi: 10.1111/jdv.19935 pmid: 38779986
[12]	Lan Y, Wu X, Zhong X, et al. Increased neutrophil-derived IL-17A identified in generalized pustular psoriasis[J]. Exp Dermatol, 2024, 33(2): e15026.
[13]	Kodali N, Blanchard I, Kunamneni S, et al. Current management of generalized pustular psoriasis[J]. Exp Dermatol, 2023, 32(8): 1204-1218.
[14]	Lu J, Yu Q, Huang D, et al. Spesolimab rapidly treats generalized pustular psoriasis and improves the skin immune microenvironment in Chinese patients[J]. Clin Immunol, 2024, 265: 110280.
[15]	Hospach T, Glowatzki F, Blankenburg F, et al. Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents[J]. Pediatr Rheumatol Online J, 2019, 17(1): 37. doi: 10.1186/s12969-019-0338-1 pmid: 31286990
[16]	Menter A, Cordoro KM, Davis D, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients[J]. J Am Acad Dermatol, 2020, 82(1): 161-201. doi: S0190-9622(19)32655-6 pmid: 31703821
[17]	《脓疱型银屑病诊疗中国专家共识(2022版) 》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识(2022版)[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
	Writing committee expert group on "diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement". Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022)[J]. Zhonghua Pifuke Zazhi, 2022, 55(3): 187-195.
[18]	Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP[J]. J Dermatol, 2018, 45(11): 1235-1270.
[19]	Miao C, Chen Y, Wang Z, et al. Real-world data on the use of secukinumab and acitretin in pediatric generalized pustular psoriasis[J]. J Dermatol, 2023, 50(2): 258-261.
[20]	王雅辰, 王召阳, 向欣, 等. 口服阿维A对106例儿童身高和骨骼发育影响的回顾性分析[J]. 中华皮肤科杂志, 2022, 55(12): 1073-1077.
	Wang YC, Wang ZY, Xiang X, et al. Effect of oral acitretin on the height and bone development of children: a retrospective analysis of 106 cases[J]. Zhonghua Pifuke Zazhi, 2022, 55(12): 1073-1077.
[21]	宋璞, 马翠玲, 樊平申, 等. 环孢素治疗儿童泛发性脓疱性银屑病临床疗效的回顾性分析[J]. 临床皮肤科杂志, 2022, 51(6): 369-372.
	Song P, Ma CL, Fan PS, et al. Clinical experience with systemic cyclosporine A treatment for childhood generalized pustular psoriasis[J]. Linchuang Pifuke Zazhi, 2022, 51(6): 369-372.
[22]	张娜, 李税琪, 李红文. 环孢素A治疗儿童泛发性脓疱型银屑病的临床效果[J]. 河南医学研究, 2020, 29(15): 2727-2729.
	Zhang N, Li SQ, Li HW. Efficacy on cyclosporine A in the treatment of childhood generalized pustule psoriasis[J]. Henan Yixue Yanjiu, 2020, 29(15): 2727-2729.
[23]	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南(2024版)[J]. 中华皮肤科杂志, 2024, 57(11): 976-997.
	Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China (2024)[J]. Zhonghua Pifuke Zazhi, 2024, 57(11): 976-997.
[24]	Du Y, Yan Q, Chen M, et al. Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review[J]. J Dermatolog Treat, 2022, 33(6): 2862-2868.
[25]	Arasiewicz H, Lesiak A, Dec M, et al. Successful treatment of a child's generalized pustular psoriasis with adalimumab in combination with low-dose acitretin[J]. Postepy Dermatol Alergol, 2023, 40(3): 464-466.
[26]	廉佳, 陈立新, 王莹, 等. 阿达木单抗联合阿维A治疗5例儿童泛发性脓疱型银屑病回顾性分析[J]. 中华皮肤科杂志, 2022, 55(10): 916-918.
	Lian J, Chen LX, Wang Y, et al. Adalimumab combined with acitretin in the treatment of five children with generalized pustular psoriasis: a retrospective clinical observation[J]. Zhonghua Pifuke Zazhi, 2022, 55(10): 916-918.
[27]	Liao K, Hou Z, Jing R, et al. Paediatric generalised pustular psoriasis with IL36RN mutation: successful treatment with adalimumab[J]. Indian J Dermatol, 2023, 68(6): 727.
[28]	Saikaly SK, Mattes M. Biologics and pediatric generalized pustular psoriasis: an emerging therapeutic trend[J]. Cureus, 2016, 8(6): e652.
[29]	Mazzotta A, Saraceno R, Esposito M, et al. Etanercept, childhood and long-term safety: a case of five years treatment[J]. Eur J Dermatol, 2011, 21(5): 776-777. doi: 10.1684/ejd.2011.1432 pmid: 21697062
[30]	Cuperus E, Koevoets R, van der Smagt JJ, et al. Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T>C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin[J]. JAAD Case Rep, 2018, 4(2): 192-195. doi: 10.1016/j.jdcr.2017.08.019 pmid: 29892664
[31]	Lu J, Li Y, Yu N, et al. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports[J]. J Int Med Res, 2020, 48(3): 300060520912091.
[32]	孙志琳, 刘子莲, 许媛媛, 等. 英夫利西单抗治疗青少年急性泛发性脓疱型银屑病1例[J]. 中华皮肤科杂志, 2023, 56(1): 69-70.
	Sun ZL, Liu ZL, Xu YY, et al. A case of acute juvenile generalized pustular psoriasis successfully treated with infliximab[J]. Zhonghua Pifuke Zazhi, 2023, 56(1): 69-70.
[33]	Pan J, Qiu L, Xiao T, et al. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab[J]. Dermatol Ther, 2016, 29(3): 164-167.
[34]	Wei K, Li P, He X, et al. Clinical efficacy and safety of secukinumab in the treatment of generalized pustular psoriasis in the pediatric population: a systematic review of the literature[J]. Front Med (Lausanne), 2024, 11: 1377381.
[35]	余敏, 应掌红. 司库奇尤单抗治疗儿童泛发性脓疱型银屑病临床分析[J]. 皮肤性病诊疗学杂志, 2024, 31(4): 226-231. doi: 10.3969/j.issn.1674-8468.2024.04.002
	Yu M, Ying ZH. Clinical analysis of secukinumab in the treatment of childhood generalized pustular psoriasis[J]. Pifuxingbing Zhenliaoxue Zazhi, 2024, 31(4): 226-231.
[36]	López-Sánchez C, Falla LM, Roé-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis[J]. J Dermatol, 2021, 48(6): 907-910.
[37]	Guevara B, Aquino J, Diaz R, et al. Infantile generalized pustular psoriasis with excellent response to secukinumab: a case report[J]. Exp Dermatol, 2023, 32(8): 1296-1298.
[38]	Chen Y, Wang Z, Liang Y, et al. Successful treatment of pediatric generalized pustular psoriasis (GPP) with spesolimab: 5 case reports and evaluations of circulating IL-36 levels[J]. J Inflamm Res, 2024, 17: 8199-8206. doi: 10.2147/JIR.S485077 pmid: 39525315
[39]	Pathak GN, Wang E, Dhillon J, et al. Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis[J]. Ann Pharmacother, 2024, 307013968.

Progress in pathogenesis and treatment of pediatric generalized pustular psoriasis

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 39

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	JIA Shichen, XU Guofeng. Advances in the diagnosis and treatment of cystinuria [J]. Journal of Clinical Pediatrics, 2026, 44(8): 740-746.
[9]	CHENG Yuheng, XU Zizhao, CHEN Ying. Recent advances in the diagnosis and treatment of X-linked hypophosphatemic rickets [J]. Journal of Clinical Pediatrics, 2026, 44(8): 747-754.
[10]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[11]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[12]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[13]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[14]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[15]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.